Sequential immunization with a subtype B HIV-1 envelope quasispecies partially mimics the in vivo development of neutralizing antibodies - Wikidata - wikimedia - TriplyDB

Sequential immunization with a subtype B HIV-1 envelope quasispecies partially mimics the in vivo development of neutralizing antibodies

Sequential immunization with a subtype B HIV-1 envelope quasispecies partially mimics the in vivo development of neutralizing antibodies

http://www.wikidata.org/entity/Q34982715

about

A global approach to HIV-1 vaccine development Virological features associated with the development of broadly neutralizing antibodies to HIV-1 Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus Viral Escape from Neutralizing Antibodies in Early Subtype A HIV-1 Infection Drives an Increase in Autologous Neutralization Breadth Humanized Immunoglobulin Mice: Models for HIV Vaccine Testing and Studying the Broadly Neutralizing Antibody Problem.Boosting of HIV-1 neutralizing antibody responses by a distally related retroviral envelope protein.HIV vaccine trial exploits a dual and central role for innate immunity.B-cell-lineage immunogen design in vaccine development with HIV-1 as a case study Envelope variants circulating as initial neutralization breadth developed in two HIV-infected subjects stimulate multiclade neutralizing antibodies in rabbits.Comparison of neutralizing antibody responses elicited from highly diverse polyvalent heterotrimeric HIV-1 gp140 cocktail immunogens versus a monovalent counterpart in rhesus macaques Multimeric scaffolds displaying the HIV-1 envelope MPER induce MPER-specific antibodies and cross-neutralizing antibodies when co-immunized with gp160 DNA HIV-1 envelope glycoprotein resistance to monoclonal antibody 2G12 is subject-specific and context-dependent in macaques and humans.Multimodality vaccination against clade C SHIV: partial protection against mucosal challenges with a heterologous tier 2 virus.Strategies to guide the antibody affinity maturation process Diverse antibody genetic and recognition properties revealed following HIV-1 envelope glycoprotein immunization.Competitive exclusion by autologous antibodies can prevent broad HIV-1 antibodies from arising.Cross-reactive broadly neutralizing antibodies: timing is everything.Sequential and Simultaneous Immunization of Rabbits with HIV-1 Envelope Glycoprotein SOSIP.664 Trimers from Clades A, B and C.Diversification in the HIV-1 Envelope Hyper-variable Domains V2, V4, and V5 and Higher Probability of Transmitted/Founder Envelope Glycosylation Favor the Development of Heterologous Neutralization Breadth Longitudinal Antigenic Sequences and Sites from Intra-Host Evolution (LASSIE) Identifies Immune-Selected HIV Variants.Motif-optimized subtype A HIV envelope-based DNA vaccines rapidly elicit neutralizing antibodies when delivered sequentially.Optimal Sequential Immunization Can Focus Antibody Responses against Diversity Loss and Distraction.Pre-existing neutralizing antibody mitigates B cell dysregulation and enhances the Env-specific antibody response in SHIV-infected rhesus macaques Neutralizing antibodies to HIV-1 induced by immunization.Achieving Potent Autologous Neutralizing Antibody Responses against Tier 2 HIV-1 Viruses by Strategic Selection of Envelope Immunogens.Induction of neutralizing antibodies in rhesus macaques using V3 mimotope peptides.HIV-1 escapes from N332-directed antibody neutralization in an elite neutralizer by envelope glycoprotein elongation and introduction of unusual disulfide bonds.Early short-term treatment with neutralizing human monoclonal antibodies halts SHIV infection in infant macaques Neutralizing polyclonal IgG present during acute infection prevents rapid disease onset in simian-human immunodeficiency virus SHIVSF162P3-infected infant rhesus macaques Improvement of antibody responses by HIV envelope DNA and protein co-immunization.Natural infection as a blueprint for rational HIV vaccine design.Prospects for an HIV vaccine: leading B cells down the right path.Neutralizing antibodies and control of HIV: moves and countermoves.Conserved immunogens in prime-boost strategies for the next-generation HIV-1 vaccines.Sequential Immunization Elicits Broadly Neutralizing Anti-HIV-1 Antibodies in Ig Knockin Mice.Development of an anti-HIV vaccine eliciting broadly neutralizing antibodies.How germinal centers evolve broadly neutralizing antibodies: the breadth of the follicular helper T cell response.Glycosylation profiling to evaluate glycoprotein immunogens against HIV-1.Mammalian cell surface display for monoclonal antibody-based FACS selection of viral envelope proteins.Anti-RAINBOW dye-specific antibodies as universal tools for the visualization of prestained protein molecular weight markers in Western blot analysis.

P2860

Q27024614-1A2488C1-6AC6-47F5-8241-E2BE05F104FA Q27025177-CE3AB8A8-19E8-4406-BAB1-56C3F3A05D51 Q27644501-47AC3D3F-7CA5-4F14-AC34-0724F942818F Q27676728-4C6121D5-55D5-43E2-BA98-FEBB3054BB0B Q30234773-B4FCAC99-D089-4ABC-A595-F62ABE379A51 Q33955745-438F5273-65B0-45B6-B3D2-B81ED32B046E Q34261579-9E65B674-8B6B-4CDD-90B2-597599B4DFCF Q34273373-EE1008DC-2054-40D4-8DF1-7F648141BF37 Q34594513-F4B811CF-827C-4AED-88F2-7A4ACD71F487 Q34663118-D2D39719-EC10-4BC3-B0B1-66C872C43FE6 Q34712503-D435FB09-2FB7-4151-9A4D-48638171F734 Q34990575-9B386FAE-A819-484F-80D2-2F87CFC119FE Q35129224-CCA462AB-176D-40EE-AD9E-E9842311AF19 Q35685300-FF25C495-8AED-401F-97AC-B0525A5B94D1 Q35691113-FB5EDBB5-D43F-41BF-8E2E-CF459C4A6F36 Q36079024-D0D384B8-F48E-4CC5-883E-60B8EC912182 Q36105782-332219F4-0BA7-4C6E-B097-B4BE5EB3A75F Q36132706-815EE85A-BB42-4B5A-91CF-8FB8297943C6 Q36194234-4A323F2D-C9DE-4E08-A79D-9C1E949CF83A Q36246646-969FA655-734E-4799-A6ED-B6EFE84B336C Q36249053-959C1392-CB30-4D13-BD7B-324C6B6BFB51 Q36263769-1B1138C9-953B-4B06-8D25-5A9E77F8F232 Q36286484-1579774D-BF87-4694-8758-8286139D2D66 Q36603515-5C2BE843-A664-4CBC-B1DB-EDBC7F2B7FF7 Q36702114-C87DE7EF-D7C2-42EB-AD58-33B52068A6A6 Q36920319-89154B97-9CA4-43D5-8DD6-785309BD03D9 Q37073506-058CBE23-54BD-4AD2-B325-1AEB3FAE729F Q37171570-58D2DFC0-9EC6-49AF-8087-18D7C52F1D87 Q37252831-86FA1831-29D4-4C10-86F6-A08030E96708 Q37588371-8FFF159B-78C9-43D7-96DC-CB4BF0E3FC3F Q37619134-847F82DF-847C-4DA1-A959-990EF6A7F100 Q37964482-051CFFB4-6FD3-42D7-AE76-44836DDDD3A9 Q37971867-9DFBEFD1-247F-4D46-8915-A037BFB62A0F Q38184579-455EF190-FC15-4E60-A1AD-DDA58E13A2FC Q39407795-2A31E192-2629-454A-87AF-027BA93ED63E Q40047250-E5729298-571B-4A85-9ADA-D4867630D178 Q40054979-ECD5347F-AC69-498C-9AF9-0BAB5E13E8EB Q40058876-23E4E18A-FEE2-43F8-AFA1-0E00FFDED821 Q40080000-AAFF17EA-0945-461D-BDA5-6F43726F8B98 Q41729241-E0F232F7-8F34-409A-9882-CC9121607FF1

P2860

Sequential immunization with a subtype B HIV-1 envelope quasispecies partially mimics the in vivo development of neutralizing antibodies

http://www.wikidata.org/entity/Q34982715

description

2011 nî lūn-bûn

@nan

2011 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի մարտին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Sequential immunization with a ...... ent of neutralizing antibodies

@ast

Sequential immunization with a ...... ent of neutralizing antibodies

@en

Sequential immunization with a ...... ent of neutralizing antibodies

@nl

type

label

Sequential immunization with a ...... ent of neutralizing antibodies

@ast

Sequential immunization with a ...... ent of neutralizing antibodies

@en

Sequential immunization with a ...... ent of neutralizing antibodies

@nl

prefLabel

Sequential immunization with a ...... ent of neutralizing antibodies

@ast

Sequential immunization with a ...... ent of neutralizing antibodies

@en

Sequential immunization with a ...... ent of neutralizing antibodies

@nl

P1433

Q34982715-C5A19EF6-EE42-43DF-AE44-D732E8C3B8D8

P1476

Q34982715-E063D816-91F5-4058-9B7C-92967F84D190

P2093

Q34982715-0FDE2F31-F605-4D58-B7B3-4EF8FBF39480

Q34982715-279EF632-0F6E-42B3-A5B1-97A3F94D412D

Q34982715-27AA6952-51DE-4FD9-A790-6E1541CB3864

Q34982715-377FBCFF-EAF9-47DB-B8EF-6EFD1445FCF3

Q34982715-4021EB13-AEDB-4BAC-B7C6-CF6570647D2F

Q34982715-43E93C8E-8159-46AD-B502-C113AF20DEBE

Q34982715-6BBC59DD-4EB1-4B21-9982-7F0F9DDF21A0

Q34982715-7C7D8949-AD19-400E-8CAC-0A967688F212

Q34982715-8B8C8D4A-C7E7-4250-A571-678028B40198

Q34982715-B8962916-D210-4687-ABEE-5E869A7B8926

P2860

Q34982715-0D9DBC18-D622-46C9-9F3D-FBE573EB863F

Q34982715-15D31C88-6EB4-4911-963F-44A6C2FBF3CE

Q34982715-19F0F052-E463-4F48-AA89-1100BA2498C6

Q34982715-21189670-B38D-4F79-91C2-1D0372AA4A50

Q34982715-25DF2740-F1A2-4BFE-89DD-379D722CB7D3

Q34982715-298DC607-A027-4342-A33E-019D71A524F8

Q34982715-2F6BF1A6-1242-42F9-9EB3-099B4B6CDA6C

Q34982715-34E3C21F-62C2-4C5E-80F3-CDB81474BB34

Q34982715-3630615D-E475-4300-B0F1-EB53618F3D3E

Q34982715-4595D540-6579-43CF-9ECE-452621C16CA9

P304

Q34982715-A4649742-6474-4908-AE83-CE7FC861A221

P31

Q34982715-9CD7078C-D235-4800-BD22-912DBA4B2834

P356

Q34982715-86DD3956-AB36-4003-A7E0-29CE912DC33E

P407

Q34982715-FD269BDC-990E-4B4B-9BDD-8ED8B1EEB3B3

P433

Q34982715-1CB6C23E-71E2-445E-BB21-0390D7ED1CAB

P478

Q34982715-DFEBDA30-463A-4951-B9F5-81971AB0C9D2

P50

Q34982715-A566D008-94B0-4C5F-B4A8-39397B28DAAC

P577

Q34982715-672924F7-AB4C-4181-8990-F090B36ED878

P698

Q34982715-8EA4E1C0-05C9-4D0F-96EF-DF951C32130E

P921

Q34982715-393B7378-441D-4793-94C1-40C41E963C50

Q34982715-E090B571-D5CB-4DB4-9803-69534A8058A8

P932

Q34982715-C5C28B50-E4E0-437A-B541-2B473CDB8F9F

P356

P1433

Journal of Virology

P1476

Sequential immunization with a ...... ent of neutralizing antibodies

@en

P2093

Delphine C Malherbe

http://www.w3.org/2001/XMLSchema#string

Indresh Srivastava

http://www.w3.org/2001/XMLSchema#string

Jason T Schuman

http://www.w3.org/2001/XMLSchema#string

Jean O'Malley

http://www.w3.org/2001/XMLSchema#string

Leonidas Stamatatos

http://www.w3.org/2001/XMLSchema#string

Lynda Misher

http://www.w3.org/2001/XMLSchema#string

Motomi Mori

http://www.w3.org/2001/XMLSchema#string

Nicole A Doria-Rose

http://www.w3.org/2001/XMLSchema#string

Susan Barnett

http://www.w3.org/2001/XMLSchema#string

Travis Beckett

http://www.w3.org/2001/XMLSchema#string

P2860

Antibody vs. HIV in a clash of evolutionary titans

Neutralizing antibody responses drive the evolution of human immunodeficiency virus type 1 envelope during recent HIV infection

Rapid cloning of high-affinity human monoclonal antibodies against influenza virus

Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates

Structural Basis for Broad and Potent Neutralization of HIV-1 by Antibody VRC01

Human Immunodeficiency Virus Type 1 Subtype B Ancestral Envelope Protein Is Functional and Elicits Neutralizing Antibodies in Rabbits Similar to Those Elicited by a Circulating Subtype B Envelope

Antibody neutralization and escape by HIV-1

Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target

Rapid evolution of the neutralizing antibody response to HIV type 1 infection

Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies

P304

5262-5274

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/JVI.02419-10

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

85

http://www.w3.org/2001/XMLSchema#string

P50

P577

2011-03-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21430056

http://www.w3.org/2001/XMLSchema#string

P921

P932

3094990

http://www.w3.org/2001/XMLSchema#string